{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:18:06Z","timestamp":1782587886646,"version":"3.54.5"},"reference-count":30,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>Acromegaly is a systemic disorder caused by a GH-secreting pituitary adenoma. As with other rare diseases, acromegaly registries developed in various European countries have provided us with important information.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>The objective of the study was to analyze the epidemiological, clinical, biochemical, and therapeutic data from the Mexican Acromegaly Registry (MAR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting:<\/jats:title>\n                  <jats:p>The setting of the study was a nationwide patient registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and Methodology:<\/jats:title>\n                  <jats:p>The MAR was created in 2009. It gathers data from 24 participating centers belonging to three different institutions using a specifically designed on-line platform. Only patients diagnosed after 1990 were included in the program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>A total of 2057 patients (51% female, mean age at diagnosis 41.1 \u00b1 24.5 y) have been registered for an estimated prevalence of 18 cases per 1 million inhabitants. Hypertension, glucose intolerance, diabetes, and dyslipidemia were present in 27%, 18.4%, 30%, and 24% of the patients, respectively. The IGF-1 level at diagnosis and the concomitant presence of hypertension were significantly associated with the development of diabetes. Transsphenoidal surgery was the primary treatment in 72% of the patients. Pharmacological treatment, mostly with somatostatin analogs, was administered primarily and adjunctively in 26% and 54% of the patients, respectively. Treatment choice varied among the three participating institutions, with the predominance of pharmacological therapy in two of them and of radiation therapy in the third. Therapeutic outcomes were similar to those reported in the European registries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>The MAR is the largest and first non-European registry of the disease. Our findings highlight important within-country differences in treatment choice due to variations in the availability of resources.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2016-1937","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T17:00:56Z","timestamp":1468861256000},"page":"3997-4004","source":"Crossref","is-referenced-by-count":76,"title":["The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes"],"prefix":"10.1210","volume":"101","author":[{"given":"Lesly A.","family":"Portocarrero-Ortiz","sequence":"first","affiliation":[{"name":"Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda (L.A.P.-O., C.V.V.-M.), 14269 Mexico City, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Vergara-Lopez","sequence":"additional","affiliation":[{"name":"Centro Medico Nacional 20 de Noviembre Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (A.V.-L.), 03100 Mexico City, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricela","family":"Vidrio-Velazquez","sequence":"additional","affiliation":[{"name":"Hospital Regional 110, Instituto Mexicano del Seguro Social (M.V.-V.), 44716 Guadalajara, Jal, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Uribe-Diaz","sequence":"additional","affiliation":[{"name":"Unidad Medica de Alta Especialidad 189 (A.M.U.-D.), 91755 Veracruz, Ver, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avril","family":"Garc\u00eda-Dominguez","sequence":"additional","affiliation":[{"name":"Unidad Medica de Alta Especialidad Manuel Avila Camacho (A.G.-D.), Instituto Mexicano del Seguro Social, 7200 Puebla, Pue, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Adolfo","family":"Reza-Albarr\u00e1n","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias Medicas y Nutricion (A.-A.R.-A., D.C.-R.), 14080 Mexico City, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cuevas-Ramos","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias Medicas y Nutricion (A.-A.R.-A., D.C.-R.), 14080 Mexico City, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgilio","family":"Melgar","sequence":"additional","affiliation":[{"name":"ABC Neurological Center (V.M., J.T., M.M.), 05300 Mexico City, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Talavera","sequence":"additional","affiliation":[{"name":"ABC Neurological Center (V.M., J.T., M.M.), 05300 Mexico City, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleida de Jesus","family":"Rivera-Hernandez","sequence":"additional","affiliation":[{"name":"Hospital General Zaragoza (A.d.J.R.-H.), Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, 09100 Mexico City, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Valentina","family":"Valencia-M\u00e9ndez","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda (L.A.P.-O., C.V.V.-M.), 14269 Mexico City, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Mercado","sequence":"additional","affiliation":[{"name":"ABC Neurological Center (V.M., J.T., M.M.), 05300 Mexico City, Mexico;"},{"name":"Hospital de Especialidades Centro Medico Nacional S.XXI, Instituto Mexicano del Seguro Social (M.M.), 01120 Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Mexican Acromegaly Registry Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2016,7,18]]},"reference":[{"key":"2020071614180369300_B1","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"key":"2020071614180369300_B2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03344942","article-title":"Acromegaly: an epidemiological study","volume":"16","author":"Etxabe","year":"1993","journal-title":"J Endocrinol Invest"},{"key":"2020071614180369300_B3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614180369300_B4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614180369300_B5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev"},{"key":"2020071614180369300_B6","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol"},{"key":"2020071614180369300_B7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/eje.0.1510439","article-title":"Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espa\u00f1ol de Acromegalia, REA)","volume":"151","author":"Mestr\u00f3n","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2020071614180369300_B8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-07-0358","article-title":"AcroBel\u2014the Belgian registry on acromegaly: a survey of the \u201creal-life\u201d outcome in 418 acromegalic subjects","volume":"157","author":"Bex","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2020071614180369300_B9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1055\/s-2006-948313","article-title":"The German acromegaly registry: description of the database and initial results","volume":"114","author":"Reincke","year":"2006","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2020071614180369300_B10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/EJE-12-0084","article-title":"Predictors of morbidity and mortality in acromegaly: an Italian survey","volume":"167","author":"Arosio","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2020071614180369300_B11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/CLEP.S63758","article-title":"Acromegaly according to the Danish Registry of Patients: how valid are ICD diagnoses and how do patterns of registration affect the accuracy of registry data","volume":"6","author":"Dal","year":"2014","journal-title":"Clin Epidemiol"},{"key":"2020071614180369300_B12","first-page":"176","article-title":"Primer reporte del registro nacional de acromegalia: Programa Epiacro","volume":"18","author":"Acevedo","year":"2010","journal-title":"Rev Endocrinol Nutr"},{"key":"2020071614180369300_B13","article-title":"\u201cEpiacro\u201d: the Mexican Acromegaly Registry","author":"Jervis"},{"key":"2020071614180369300_B14","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.2337\/diacare.26.11.3160","article-title":"Follow-up report on the diagnosis of diabetes mellitus","volume":"26","author":"Genuth","year":"2003","journal-title":"Diabetes Care"},{"key":"2020071614180369300_B15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/EJE-12-0602","article-title":"Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register","volume":"168","author":"Schofl","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2020071614180369300_B16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1530\/EJE-07-0356","article-title":"Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly","volume":"157","author":"T\u2019Sjoen","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2020071614180369300_B17","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1210\/jc.2007-2104","article-title":"Divergence between growth hormone and insulin-like growth factor-1 concentrations in the follow-up of acromegaly","volume":"93","author":"Alexopoulou","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614180369300_B18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11102-012-0384-x","article-title":"Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA)","volume":"16","author":"Sesmilo","year":"2013","journal-title":"Pituitary"},{"key":"2020071614180369300_B19","first-page":"519","article-title":"Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey","volume":"52","author":"Villalpando","year":"2010","journal-title":"Salud Publ Mex"},{"key":"2020071614180369300_B20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11102-010-0284-x","article-title":"Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism","volume":"14","author":"Espinosa-de-los-Monteros","year":"2011","journal-title":"Pituitary"},{"key":"2020071614180369300_B21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2265.2005.02370.x","article-title":"Hypertension in acromegaly and in the normal population: prevalence and determinants","volume":"63","author":"Vitale","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614180369300_B22","first-page":"293","article-title":"Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease","volume":"62","author":"Mercado","year":"2004","journal-title":"Horm Res"},{"key":"2020071614180369300_B23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1507\/endocrj.42.781","article-title":"Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-1 production","volume":"42","author":"Ohtsuka","year":"1995","journal-title":"Endocr J"},{"key":"2020071614180369300_B24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1563-2571.2000.00106.x","article-title":"Prevalence of diabetes in acromegaly and Cushing\u2019s syndrome","volume":"27","author":"Biering","year":"2002","journal-title":"Acta Med Austr"},{"key":"2020071614180369300_B25","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1210\/jc.2004-2009","article-title":"Relationship between disease-related morbidities and biochemical markers of activity in patients with acromegaly","volume":"90","author":"Puder","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614180369300_B26","first-page":"20","article-title":"Abnormalities in glucose homeostasis in acromegaly: does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms?","volume":"60","author":"Stelmachowska-Banas","year":"2009","journal-title":"Endokrynol Pol"},{"key":"2020071614180369300_B27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/jc.2003-030915","article-title":"Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly","volume":"89","author":"Serri","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614180369300_B28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-08-0498","article-title":"Results of surgical and somatostatin analog therapies and their combinations in acromegaly: a retrospective analysis of the German Acromegaly Register","volume":"159","author":"Petersenn","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2020071614180369300_B29","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide vs. octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614180369300_B30","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicentre phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/101\/11\/3997\/10527768\/jcem3997.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/101\/11\/3997\/10527768\/jcem3997.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:53:56Z","timestamp":1594950836000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/101\/11\/3997\/2764931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,18]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2016-1937","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,18]]}}}